3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
2
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
220
Urinary Bladder Neoplasms
54
Carcinoma, Renal Cell
53
Neoplasms
27
Non-Muscle Invasive Bladder Neoplasms
26
Kidney Neoplasms
25
Breast Neoplasms
17
Carcinoma, Transitional Cell
15
Adenocarcinoma
15
Melanoma
11
Disease
11
Neoplasm Metastasis
10
Colorectal Neoplasms
10
Uterine Cervical Neoplasms
9
Endometrial Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Stomach Neoplasms
7
Ovarian Neoplasms
7
Lung Neoplasms
7
Clear-cell metastatic renal cell carcinoma
7
Triple Negative Breast Neoplasms
6
Testicular Neoplasms
6
Recurrence
6
Urologic Neoplasms
5
Urinary Incontinence
5
Squamous Cell Carcinoma of Head and Neck
5
Sarcoma
5
Pancreatic Neoplasms
5
Head and Neck Neoplasms
5
Carcinoma, Hepatocellular
5
Interventions
pembrolizumab
1
enfortumab vedotin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Advanced Bladder Cancer
×
Genitourinary
×
Clear all
NCT07346053
2026-01-16
Chrono-EVP
British Columbia Cancer Agency
Phase 3
Not yet recruiting
224 enrolled
NCT07204496
2025-10-02
γδ-T-BLADDER
Shanghai 10th People's Hospital
Not yet recruiting
20 enrolled